Tepnel Pharma Services (Tepnel), a business unit of Hologic, Inc., has expanded its portfolio of services to include companion diagnostic development, the company announced today. The companion diagnostic development service will build on Tepnel’s reputation as a world class contract research organization specializing in molecular genetic services.
The growth in companion diagnostic development has been significant as costs associated with drug discovery, development and launch continue to rise, and as demand for patient-tailored solutions for disease increases. Companion diagnostic development has the potential to decrease drug development time and expense, while at the same time enhancing therapeutic efficacy. Tepnel will utilize both its proprietary and non-proprietary technology platforms in this new comprehensive service.
“Companion diagnostic development is a valuable addition to Tepnel’s portfolio of services and an exciting next step in the evolution of our genomics business”, said David Scott, Senior Director, Tepnel Pharma Services. “Our knowledge and understanding of the drug development process, coupled with Hologic’s expertise in the diagnostic industry, create a service platform that will support each phase of our customers’ development initiatives. Our new service offers our customers flexibility, and state-of-the-art technologies that should result in the availability of diagnostic tools designed to improve patient outcomes whilst meeting the economic demands of healthcare systems”.
About Tepnel Pharma Services
Tepnel Pharma Services is the Contract Research Organization (CRO) arm of Hologic, Inc. Tepnel specialises in the provision of pharmaceutical testing and molecular genetic services in support of drug development and companion diagnostics development. Tepnel’s pharmaceutical testing facilities are located in Manchester, England and Livingston, Scotland.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company’s core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure. For more information on Hologic, visit www.hologic.com.
Hologic, Tepnel Pharma Services, The Science of Sure and associated logos are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statements Disclaimer
This press release may contain forward-looking information that involves risks and uncertainties, including statements about Hologic, Inc., Tepnel Pharma Services and the companion diagnostic development service. There can be no assurance this service will achieve the results described herein and that such results will be replicated in any particular manner with respect to an individual customer as results may vary on a case-by-case basis. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein or to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
Carol Smith Marianne McMorrow
Marketing Communications Manager Manager, Corporate Communications
Hologic, Inc. Hologic, Inc.
Tel: + 44 (0) 161 946 2220 Tel: +011 781 999 7723